Orthocell (ASX:OCC) secured approval to market and sell its Remplir nerve repair collagen wrap from the Singaporean Health Science Authority, according to a Tuesday filing with the Australian bourse.
This is the first approval for the device outside of Australia and New Zealand in a country considered to be the gateway for the ASEAN market, the filing said.
The device is expected to be distributed to the Singaporean market by the first quarter of next year, as per the filing.
The company's shares rose past 5% in recent Tuesday trade and earlier hit their highest level since May 2021.
Price (AUD): $0.51, Change: $+0.03, Percent Change: +5.21%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。